CN102740870B - 日本路边青有机提取物在制备用于治疗或预防高血压药物中的用途 - Google Patents

日本路边青有机提取物在制备用于治疗或预防高血压药物中的用途 Download PDF

Info

Publication number
CN102740870B
CN102740870B CN201080026126.6A CN201080026126A CN102740870B CN 102740870 B CN102740870 B CN 102740870B CN 201080026126 A CN201080026126 A CN 201080026126A CN 102740870 B CN102740870 B CN 102740870B
Authority
CN
China
Prior art keywords
oegj
purposes
acid
blood pressure
hypertension
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080026126.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN102740870A (zh
Inventor
李明
彭鹏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Generex Pharmaceuticals Inc
Original Assignee
Generex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generex Pharmaceuticals Inc filed Critical Generex Pharmaceuticals Inc
Publication of CN102740870A publication Critical patent/CN102740870A/zh
Application granted granted Critical
Publication of CN102740870B publication Critical patent/CN102740870B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
CN201080026126.6A 2009-06-12 2010-06-11 日本路边青有机提取物在制备用于治疗或预防高血压药物中的用途 Expired - Fee Related CN102740870B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US18670909P 2009-06-12 2009-06-12
US61/186,709 2009-06-12
US18790509P 2009-06-17 2009-06-17
US61/187,905 2009-06-17
PCT/IB2010/001412 WO2010143059A1 (en) 2009-06-12 2010-06-11 Compositioins and preparation methods of compositions for prevention and treatment of hypertension

Publications (2)

Publication Number Publication Date
CN102740870A CN102740870A (zh) 2012-10-17
CN102740870B true CN102740870B (zh) 2016-06-29

Family

ID=43308481

Family Applications (6)

Application Number Title Priority Date Filing Date
CN201080026126.6A Expired - Fee Related CN102740870B (zh) 2009-06-12 2010-06-11 日本路边青有机提取物在制备用于治疗或预防高血压药物中的用途
CN201080030503.3A Expired - Fee Related CN102548560B (zh) 2009-06-12 2010-06-11 用于预防和治疗冠心病的组合物和方法
CN201080026128.5A Expired - Fee Related CN102573865B (zh) 2009-06-12 2010-06-11 用于预防和治疗红细胞聚集的组合物
CN201080026127.0A Expired - Fee Related CN102497873B (zh) 2009-06-12 2010-06-11 用于增加生存年限和健康年限的组合物和方法
CN201080026141.0A Expired - Fee Related CN102711768B (zh) 2009-06-12 2010-06-11 用于预防和治疗心衰的组合物和方法
CN201080030502.9A Expired - Fee Related CN102548571B (zh) 2009-06-12 2010-06-11 用于预防和治疗脑部疾病和疾病状态的组合物和方法

Family Applications After (5)

Application Number Title Priority Date Filing Date
CN201080030503.3A Expired - Fee Related CN102548560B (zh) 2009-06-12 2010-06-11 用于预防和治疗冠心病的组合物和方法
CN201080026128.5A Expired - Fee Related CN102573865B (zh) 2009-06-12 2010-06-11 用于预防和治疗红细胞聚集的组合物
CN201080026127.0A Expired - Fee Related CN102497873B (zh) 2009-06-12 2010-06-11 用于增加生存年限和健康年限的组合物和方法
CN201080026141.0A Expired - Fee Related CN102711768B (zh) 2009-06-12 2010-06-11 用于预防和治疗心衰的组合物和方法
CN201080030502.9A Expired - Fee Related CN102548571B (zh) 2009-06-12 2010-06-11 用于预防和治疗脑部疾病和疾病状态的组合物和方法

Country Status (6)

Country Link
US (7) US9629884B2 (enExample)
EP (6) EP2440222A4 (enExample)
JP (11) JP5827618B2 (enExample)
CN (6) CN102740870B (enExample)
AU (11) AU2010258352B2 (enExample)
WO (6) WO2010143063A1 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12397008B2 (en) * 2006-04-13 2025-08-26 Lead Billion Limited Pharmaceutical composition and method for regenerating myofibers in the treatment of muscle injuries
WO2010143063A1 (en) 2009-06-12 2010-12-16 Generex Pharmaceuticals, Inc. Compositions and methods for prevention and treatment of brain diseases and conditions
CN103282371A (zh) * 2010-12-23 2013-09-04 沪亚生物国际有限责任公司 纯化的心肌生成素异构体及相关方法
JP6000521B2 (ja) * 2011-08-10 2016-09-28 株式会社ブルボン 血圧上昇抑制剤
EP2812005B8 (en) 2012-05-16 2018-10-31 Prairie Berry Europe GmbH Polyhydroxylated pentacyclic triterpene acids as hmg-coa reductase inhibitors
US20140044813A1 (en) * 2012-08-09 2014-02-13 Kemin Industries, Inc. Plant Extracts for Improving Cognitive Health and Function
CN103623753B (zh) * 2013-11-27 2016-03-23 大兴安岭嘉迪欧营养原料有限公司 大兴安岭野生金老梅总三萜提取物的制备方法
CN103623082B (zh) * 2013-11-29 2016-08-17 江西中医药大学 覆盆子提取物及其应用
US20150174057A1 (en) * 2013-12-24 2015-06-25 Generex Pharamaceutics Inc. Compositions and methods for the prevention and treatment of oral diseases
JP2017507125A (ja) * 2014-01-30 2017-03-16 ケミン、インダストリーズ、インコーポレーテッドＫｅｍｉｎ Ｉｎｄｕｓｔｒｉｅｓ， Ｉｎｃ． 認知機能を向上させるための植物抽出物
CN105311030B (zh) * 2014-06-06 2020-03-24 正大天晴药业集团股份有限公司 用于抗肿瘤的螺取代化合物
CN104971091B (zh) * 2015-06-03 2019-08-13 兴明生物医药技术(上海)有限公司 一种用于制备促进心肌再生药物的提取物的制备方法及其应用
WO2017019182A1 (en) 2015-07-24 2017-02-02 Northeastern University Quantitative magnetic resonance imaging of the vasculature
CA2997659C (en) * 2015-09-04 2023-08-01 Reto ASMIS Methods for treatment of monocyte dysfunction and chronic inflammatory micro- and macro-vascular diseases
CN105106222B (zh) * 2015-09-14 2020-05-08 新乡医学院 吐曼酸在制备治疗或预防雌激素缺乏引起的阿尔茨海默病药物中的应用
CN106581006B (zh) * 2015-10-16 2019-11-29 香港理工大学深圳研究院 三萜类化合物在制备治疗帕金森药物中的应用
CN106153761B (zh) * 2016-06-07 2018-08-14 贵州师范大学 同时检测无籽刺梨果实中3种黄酮类成分的方法
TWI765895B (zh) 2016-06-20 2022-06-01 美商蝴蝶網路公司 用於協助使用者操作超音波裝置的自動化影像獲取之系統和方法
JP7207710B2 (ja) * 2016-11-02 2023-01-18 テンプル・ユニバーシティ－オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション 血液の粘度を低減し、血液循環内の乱流を抑制し、連銭を治療するシステム及び方法
MY203822A (en) * 2017-04-25 2024-07-19 Buck Inst Res Aging Formulations for extending lifespan and healthspan
CN106946971A (zh) * 2017-04-28 2017-07-14 南宁馨艺荣生物科技有限公司 一种从积雪草中提取积雪草酸的工艺
CN107445855B (zh) * 2017-08-07 2018-12-14 绍兴市逸晨医疗科技有限公司 一种盐酸多西环素杂质c的制备方法
JPWO2019172174A1 (ja) * 2018-03-05 2021-02-12 日本新薬株式会社 Ｒａｇｅシグナル阻害作用をもつ食品素材
MX2020009237A (es) * 2018-03-06 2021-04-28 Epibone Inc Composiciones inyectables de reparacion de cartilagos, tendones y ligamentos fuera del estante y metodos de uso.
CN112788988A (zh) * 2018-07-27 2021-05-11 东北大学 血管磁共振成像对痴呆的诊断
KR102152182B1 (ko) * 2018-09-05 2020-09-04 한국식품연구원 큰뱀무 추출물을 유효성분으로 함유하는 우울 증상 또는 스트레스의 개선, 예방 또는 치료용 조성물
SG11202102204PA (en) 2018-09-25 2021-04-29 Ponce De Leon Health Designated Activity Company Process of making calcium alpha-ketoglutarate
CA3122711A1 (en) 2018-12-21 2020-06-25 Arlanxeo Singapore Pte. Ltd. Halogen recovery in a process for halogenating unsaturated isoolefin copolymer
CN109884222B (zh) * 2019-01-17 2021-07-13 贵州中医药大学 一种小花清风藤的hplc指纹图谱建立方法
KR102152174B1 (ko) * 2020-03-30 2020-09-04 한국식품연구원 큰뱀무 추출물을 유효성분으로 함유하는 인지기능 장애의 개선, 예방 또는 치료용 조성물
CN111643556A (zh) * 2020-07-16 2020-09-11 杭州科倍安生物制药有限公司 一种用于预防和治疗痔疮的药物及其应用
WO2022043407A1 (fr) 2020-08-25 2022-03-03 Laouarem Yousra Compositions destinées au traitement des troubles neurologiques
KR102574207B1 (ko) * 2020-12-03 2023-09-04 경북대학교 산학협력단 뱀무 추출물을 유효성분으로 하는 혈전성 질환 치료 또는 예방용 조성물
CN112587599A (zh) * 2021-01-11 2021-04-02 贵州中医药大学 一种预防急性高原反应的中药组合物
CN112755079A (zh) * 2021-01-18 2021-05-07 杭州科倍安生物制药有限公司 一种预防血栓形成或溶解已形成血栓的药物及其制备方法
CN113367166B (zh) * 2021-05-13 2022-07-26 海南大学 一种褐背蒲桃提取物杀菌剂及其制备方法和应用
CN114028459A (zh) * 2021-11-11 2022-02-11 杭州科贝生物制药有限公司 预防和治疗哺乳动物缺血性心脏病的药物和制备方法及应用
CN114722066B (zh) * 2022-03-23 2023-04-07 电子科技大学 一种预测材料自旋霍尔电导及反常霍尔电导的方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1895461A (zh) * 2006-06-28 2007-01-17 海南晨菲药业有限公司 一种大青根注射剂制备工艺
KR20090020279A (ko) * 2007-08-23 2009-02-26 대한민국(관리부서:농촌진흥청) 3,4,5-트리히드록시벤즈알데히드를 유효성분으로 포함하는고지혈증 및 ｍｍｐ 과다활성으로 인한 혈관질환 예방 및치료용 조성물

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
JP2871763B2 (ja) * 1989-12-15 1999-03-17 株式会社資生堂 テストステロン―５α―レダクターゼ阻害剤
CN1069629A (zh) 1991-08-27 1993-03-10 段民生 一种康复面的制备方法
CN1047089C (zh) * 1992-12-03 1999-12-08 张斌 治疗近视眼的药物及制备工艺
JPH07179347A (ja) * 1993-12-21 1995-07-18 Showa Shell Sekiyu Kk 抗ウイルス組成物
CN1102993A (zh) 1993-12-21 1995-05-31 吴文才 多酶体系加工中草药的制剂方法
US5589154A (en) 1994-11-22 1996-12-31 Rutgers, The State University Of New Jersey Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease
DE69837551T2 (de) 1997-05-15 2007-12-20 University Of Washington, Seattle Zusammensetzung und verfahren zur behandlung der alzheimer'schen krankheit und anderen amyloidosen
CN1176814A (zh) * 1997-06-26 1998-03-25 李静 预防和治疗脑血管病的口服液
CN1102399C (zh) * 2000-06-09 2003-03-05 张庆玉 降脂通脉胶囊
AU2001278341A1 (en) * 2000-07-26 2002-02-05 Vitaplant Ag Piper methysticum plant extract
AU2001283038A1 (en) * 2000-07-31 2002-02-13 University Of Virginia Patent Foundation Inhibitors of dna polymerase sigma
US6629835B2 (en) 2000-08-01 2003-10-07 Metaproteomics, Llc Combinations of diterpene triepoxide lactones and ditepene lactones or triterpenes for synergistic inhibition of cyclooxygenase-2
JP2002255804A (ja) * 2001-03-02 2002-09-11 Suntory Ltd インシュリン様作用を有するヘキサオキシジフェン酸誘導体を含んでなる組成物
WO2002078468A1 (fr) 2001-03-30 2002-10-10 The Nisshin Oillio, Ltd. Aliment ou boisson pour maladie ou trouble vasculaire
KR100453569B1 (ko) * 2001-09-11 2004-10-20 대한민국 3,4,5-트리히드록시벤즈알데히드를 유효성분으로 포함하는항산화제
JP2003201229A (ja) 2001-10-23 2003-07-18 Shiseido Co Ltd マトリックスメタロプロテアーゼ活性阻害剤および抗老化用化粧料
PT1446134E (pt) * 2001-11-21 2010-12-17 Univ Hong Kong Chinese Composição compreendendo extractos orgânicos de geum japonicum thunb var. e sua utilização
JP4393777B2 (ja) * 2002-03-19 2010-01-06 株式会社ファンケル 抗ヘリコバクター・ピロリ用組成物
JP4498145B2 (ja) * 2002-12-10 2010-07-07 ザ・チャイニーズ・ユニバーシティー・オブ・ホンコン ダイコンソウの有機抽出物を含む治療用組成物およびダイコンソウの有機抽出物の使用
CN1239155C (zh) 2003-01-23 2006-02-01 北京中医药大学 一种治疗缺血性脑中风的药物组合物及其制备方法
US20040247698A1 (en) * 2003-06-04 2004-12-09 Valenzuela Cortes Carmen Maria Erectile Dysfunction Treatment
CN100518742C (zh) * 2003-10-10 2009-07-29 Sk化学株式会社 有效改善脑功能的三萜化合物
CN1185007C (zh) * 2003-12-08 2005-01-19 张小朋 降脂溶栓药物
CN100509008C (zh) * 2004-04-12 2009-07-08 赵晓昂 舒痛方及其制剂和用途
WO2006054370A1 (en) * 2004-11-16 2006-05-26 Use-Techno Corporation Gluconeogenesis inhibiting agent
KR100704003B1 (ko) * 2005-06-10 2007-04-06 안동대학교 산학협력단 2-알파-하이드록시-올레아놀산을 함유하는 트롬빈 저해혈전증 예방 및 치료용 조성물
JP2006347967A (ja) * 2005-06-16 2006-12-28 Yuusu Techno Corporation:Kk 血糖値上昇抑制剤
WO2007049088A1 (en) 2005-10-27 2007-05-03 Lead Billion Limited Method of stimulating growth of functional blood vessels and/or regeneration of myocardium in damaged tissues
JP5117386B2 (ja) 2005-10-27 2013-01-16 リード ビリオン リミテッド 筋傷害の治療における筋線維の再生のための医薬組成物及び方法
WO2007049089A1 (en) * 2005-10-27 2007-05-03 Lead Billion Limited Method of stimulating growth of functional blood vessels and/or regeneration of myocardium in damaged tissues
KR100718602B1 (ko) * 2005-12-29 2007-06-21 대한민국 항비만 및 항염증 효과를 가지는 뱀무 추출물, 이를포함하는 식품 조성물 및 이들의 제조 방법
JP2007204447A (ja) * 2006-02-03 2007-08-16 Yoshihiro Futamura 中性脂肪減少作用を呈するカルニチン誘導体、それからなる抗肥満薬、食品製剤及びセルライト減少作用を呈する化粧品
JP4731350B2 (ja) 2006-02-17 2011-07-20 丸善製薬株式会社 抗老化剤、皮膚化粧料及び美容用飲食品
EP1993580A4 (en) * 2006-03-16 2009-12-09 Moleac Pte Ltd COMBINED THERAPY FOR THE TREATMENT OF PATIENTS WITH NEUROLOGICAL DISORDERS AND CEREBRAL INFARCTION
CN1857627B (zh) * 2006-04-12 2010-05-19 贵阳利多药物技术开发有限公司 治疗中风的中药制剂及其制备方法
US8821947B2 (en) * 2006-06-01 2014-09-02 Howard W. Selby, III Cholesterol-reducing diet
CN101091751A (zh) * 2006-06-22 2007-12-26 北京中医药大学 一种治疗高血压的中药组合物及其制备方法
JP5281234B2 (ja) * 2006-06-27 2013-09-04 ポーラ化成工業株式会社 毛様体過緊張による疲れ目の改善・予防のための経口投与組成物
CN101099770A (zh) 2006-07-04 2008-01-09 北京中医药大学 一种具有咪唑啉受体激动活性的药物组合物及制备方法和应用
JP2008074801A (ja) * 2006-09-25 2008-04-03 Oriza Yuka Kk 肝保護剤
JP5366358B2 (ja) * 2006-09-29 2013-12-11 株式会社コーセー 皮膚の老化機構に作用する剤、抗老化用皮膚外用剤、及び抗老化方法
CN101040901A (zh) 2007-04-12 2007-09-26 云南龙润药业有限公司 迷迭香提取物及其制备方法和应用
US9205112B2 (en) 2007-04-23 2015-12-08 Creative Medical Health, Inc. Combination treatment of cardiovascular disease
US20100189830A1 (en) 2007-05-21 2010-07-29 Zhijun Liu Sweet Gum Fruit Extract as a Therapeutic Agent
US20090022827A1 (en) * 2007-07-19 2009-01-22 Ming Li Agent and method for eliminating malignance of cancer cells without harmful effect to normal cells
CN101125171B (zh) * 2007-08-20 2010-05-26 刘凤元 一种男、女补强中药
CN101406537B (zh) * 2007-10-11 2013-05-15 首都医科大学 柔毛水杨梅提取物用于制备治疗肥胖的药物的用途
CN101274012B (zh) * 2008-01-23 2011-12-28 上海海天医药科技开发有限公司 夏枯草属植物提取物的组合物、制备方法及其药物用途
WO2010143063A1 (en) 2009-06-12 2010-12-16 Generex Pharmaceuticals, Inc. Compositions and methods for prevention and treatment of brain diseases and conditions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1895461A (zh) * 2006-06-28 2007-01-17 海南晨菲药业有限公司 一种大青根注射剂制备工艺
KR20090020279A (ko) * 2007-08-23 2009-02-26 대한민국(관리부서:농촌진흥청) 3,4,5-트리히드록시벤즈알데히드를 유효성분으로 포함하는고지혈증 및 ｍｍｐ 과다활성으로 인한 혈관질환 예방 및치료용 조성물

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
《蓝布正总提取物对高血糖动物降血糖作用的研究》;洪小凤等;《大理学报》;20071031;第6卷(第10期);7-9 *
《蓝布正水提物对大鼠离体胸主动脉环的舒张作用》;文玉高等;《云南中医中药杂志》;20081231;第29卷(第9期);47-48 *

Also Published As

Publication number Publication date
JP2012529484A (ja) 2012-11-22
AU2010258352A1 (en) 2012-02-02
JP2012529487A (ja) 2012-11-22
AU2010258351A1 (en) 2012-02-02
EP2440221A1 (en) 2012-04-18
US20120076878A1 (en) 2012-03-29
CN102497873A (zh) 2012-06-13
AU2017202572B2 (en) 2019-02-21
JP5892929B2 (ja) 2016-03-23
AU2010258356A1 (en) 2012-02-02
CN102573865B (zh) 2016-08-24
AU2010258356B2 (en) 2017-01-19
CN102548571B (zh) 2014-08-27
AU2017202573B2 (en) 2019-02-21
AU2017202572A1 (en) 2017-05-11
AU2010258354B2 (en) 2015-08-13
CN102497873B (zh) 2016-04-13
CN102740870A (zh) 2012-10-17
EP2440222A1 (en) 2012-04-18
AU2017202573A1 (en) 2017-05-11
CN102548571A (zh) 2012-07-04
WO2010143059A1 (en) 2010-12-16
CN102573865A (zh) 2012-07-11
AU2018202291A1 (en) 2018-04-26
EP2440220A4 (en) 2012-12-12
JP2015155468A (ja) 2015-08-27
EP2440212A1 (en) 2012-04-18
US20120148691A1 (en) 2012-06-14
EP2440221A4 (en) 2012-12-12
AU2010258351B2 (en) 2015-05-21
JP2015164963A (ja) 2015-09-17
AU2016201525A1 (en) 2016-03-24
JP2012529485A (ja) 2012-11-22
JP5827618B2 (ja) 2015-12-02
AU2010258358B2 (en) 2015-12-10
EP2440220A1 (en) 2012-04-18
EP2440222A4 (en) 2012-12-12
WO2010143061A1 (en) 2010-12-16
JP2012529488A (ja) 2012-11-22
AU2010258358A1 (en) 2012-02-02
US20120177759A1 (en) 2012-07-12
JP2012529486A (ja) 2012-11-22
EP2440209A1 (en) 2012-04-18
US20120077762A1 (en) 2012-03-29
US9050277B2 (en) 2015-06-09
JP2012529483A (ja) 2012-11-22
CN102548560B (zh) 2016-01-20
JP6076737B2 (ja) 2017-02-08
JP5892928B2 (ja) 2016-03-23
US9283255B2 (en) 2016-03-15
US20180055896A1 (en) 2018-03-01
WO2010143058A1 (en) 2010-12-16
EP2440209A4 (en) 2013-03-20
US9950019B2 (en) 2018-04-24
JP2017128608A (ja) 2017-07-27
JP2015164967A (ja) 2015-09-17
CN102711768B (zh) 2014-04-09
JP2015164966A (ja) 2015-09-17
WO2010143062A1 (en) 2010-12-16
AU2010258354A1 (en) 2012-02-02
WO2010143065A1 (en) 2010-12-16
AU2010258355B2 (en) 2016-04-28
EP2440223A1 (en) 2012-04-18
JP6187831B2 (ja) 2017-08-30
WO2010143063A1 (en) 2010-12-16
US20120082741A1 (en) 2012-04-05
CN102711768A (zh) 2012-10-03
US9629884B2 (en) 2017-04-25
CN102548560A (zh) 2012-07-04
EP2440212A4 (en) 2013-03-20
EP2440223A4 (en) 2012-12-12
JP5689117B2 (ja) 2015-03-25
JP5712207B2 (ja) 2015-05-07
AU2010258355A1 (en) 2012-02-02
AU2016202674A1 (en) 2016-05-19
US20120077761A1 (en) 2012-03-29
AU2010258352B2 (en) 2016-04-28

Similar Documents

Publication Publication Date Title
CN102740870B (zh) 日本路边青有机提取物在制备用于治疗或预防高血压药物中的用途
AU2023274063A1 (en) Deuterated or a non-deuterated molecule and pharmaceutical formulations
JP2015163635A (ja) Ｌ−オルニチンフェニル酢酸塩を用いる門脈圧亢進の治療及び肝機能の修復
Lin et al. Protective effect of hispidulin on kainic acid-induced seizures and neurotoxicity in rats
KR20140069178A (ko) 다발성 경화증 치료용 ｓ１ｐ 수용체 조절제
JP2019537628A (ja) 併用療法
Zhang et al. Paricalcitol improves experimental autoimmune encephalomyelitis (EAE) by suppressing inflammation via NF-κB signaling
Xing et al. Astragalin mitigates inflammatory osteolysis by negatively modulating osteoclastogenesis via ROS and MAPK signaling pathway
RU2701720C1 (ru) Комбинации пальмитоилэтаноламида для лечения хронической боли
TWI464147B (zh) 吲哚氫胺酸和吲哚啉氫胺酸於治療心臟衰竭或神經損傷的用途
TWI544921B (zh) 蛇床子素用於製備治療局部腎絲球硬化症之組合物的用途
CN101146541A (zh) 用于治疗中枢神经系统疾病的方法和组合物
Zhang et al. Ibuprofen treatment ameliorates memory deficits in rats with collagen-induced arthritis by normalizing aberrant MAPK/NF-κB and glutamatergic pathways
Li et al. Rapamycin protects against neuronal death and improves neurological function with modulation of microglia after experimental intracerebral hemorrhage in rats
KR20170007426A (ko) 신장 섬유증을 억제하기 위한 진세노사이드 m1의 용도
JP2008517901A (ja) 経口で有効なカンナビノイド類似体
JP2022533603A (ja) １５－ＨＥＰＥおよび／または１５－ＨＥＴｒＥを含む組成物、ならびに心血管代謝性疾患、メタボリックシンドローム、および／または関連疾患を治療または予防する方法
KR102483150B1 (ko) 혈관 염증의 치료 또는 혈관 내피 기능 개선에 있어서의 트리아세틸-3-하이드록시 페닐 아데노신의 용도
CN112076187B (zh) 安卓锭在制备用于预防或治疗非酒精性脂肪肝的药物中的用途
JP7233087B2 (ja) 抗動脈硬化剤
RU2783498C2 (ru) Пути применения триацетил-3-гидроксифениладенозина в лечении воспалительных процессов в сосудах или улучшении функций эндотелия сосудов
CN120189408A (zh) 吲哚布芬与丁苯酞联用在制备预防和/或治疗脑血管疾病药物中的应用
CN120131645A (zh) 1-（3-氨基丙基）取代环状胺类化合物的用途
US20090036529A1 (en) Therapeutic agent for functional brain disease
US20170049737A1 (en) (2r)-2-propyloctanoic acid for functional brain disease

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160629

Termination date: 20170611